Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

The TeGenero Incident and the Duff Report Conclusions: A Series of Unfortunate Events or an Avoidable Event?

Horvath, Christopher J., Milton, Mark N. · 2009 · Toxicologic Pathology

Abstract

The administration of the first dose of a novel pharmaceutical compound to humans is the culmination of many years of efforts by many people. There is often a feeling of relief that the compound has made it this far and a feeling of great optimism and anticipation. However, it also can be a time of great trepidation because it is the first opportunity to determine the accuracy of the projections of the compound’s efficacy, ADME (absorption, distribution, metabolism, and elimination) properties, and most important, safety in humans. The administration of the first dose to humans usually results in a celebration by the development project team, although the first few dose levels of the initial clinical trial are usually uneventful and not much can be learned regarding the compound’s efficacy, ADME properties, and safety due to the low doses used in these initial dose cohorts. This is particularly true for nononcology compounds that are typically evaluated first in normal healthy volunteers (NHV) who would be expected to derive no benefit from the compound and thus generally receive a first-in-human (FIH) dose that is not anticipated to have pharmacologic activity. Unfortunately, in some instances, things do not go as anticipated. Sometimes it is learned from these early dose cohorts that the projections of the pharmacokinetics (PK) of the compound are wrong, or that the compound will not be as efficacious in humans as in animals. Sometimes the compound is found to have a side-effect profile in humans that was not predicted from the animal toxicology studies. Usually such side effects are relatively benign, consisting of headaches, nausea, drowsiness and other nuisance events which would have been difficult to appreciate in animal studies. On very rare occasions, the side effects may be more severe and, even more rarely, life-threatening. One such example of the latter was the ‘‘TeGenero Incident’’ (Expert Group on Phase One Clinical Trials 2006; Gambrill 2006). Serious, life-threatening adverse events were observed in all dosed subjects after the administration of TGN1412, a new class of monoclonal antibody (mAb) with a stimulatory mode of action on a subset of T cells known as regulatory T cells (Tregs; Expert Group on Phase One Clinical Trials 2006). This antibody was a humanized IgG4k mAb that was derived from the precursor mouse mAb 5.11A1 by grafting of the complementarity-determining regions (CDR). TGN1412 binds to CD28 and activates T cells without need for T cell receptor (TCR) preactivation, resulting in polyclonal T cell expansion and activation and concentration-dependent IL-2 production. As such, TGN1412 was termed a ‘‘superagonist.’’ The intent was to develop TGN1412 as a treatment for B cell chronic lymphocytic leukemia, in which T cells are deficient, and for autoimmune diseases, such as rheumatoid arthritis, in which Treg cell expansion might be beneficial. The TeGenero incident spurred a subsequent investigation by an expert scientific group (ESG) on Phase 1 Clinical Trials, appointed by the Medicines and Healthcare Products Regulatory Agency (MHRA) and under the leadership of Professor Gordon Duff, which culminated in a report known as ‘‘the Duff Report.’’ The objective of this article is to review the TeGenero incident and the Duff Report and to comment on whether the TeGenero incident was predictable and/or avoidable. Address correspondence to: Christopher Horvath, DVM, MS, DACVP, Vice President, PreClinical Sciences, Taligen Therapeutics, Cambridge, MA 02142; e-mail: chorvath@taligentherapeutics.com. Abbreviations: ABPI, Association of the British Pharmaceutical Industry; ADME, Absorption, Distribution, Metabolism, and Excretion; BBC, British Broadcasting Company; BIA, BioIndustry Association; CBER, FDA Center for Biologics Evaluation and Research; CD, cluster of differentiation; CDER, FDA Center for Drug Evaluation and Research; CDR, complementaritydetermining region; CHM, Commission on Human Medicines; CHMP, Committee for Medicinal Products for Human Use; CPMP, Committee for Proprietary Medicinal Products; CRS, cytokine release syndrome; CTA, clinical trial authorization; DIC, disseminated intravascular coagulation; DLT, doselimiting toxicity; EAG, expert advisory group; Emax, maximum effect; EMEA, European Medicines Agency; ESG, Expert Scientific Group on Phase 1 Clinical Trials; EU, European Union; EUDRA, European Drug Regulatory Authorities; Fc, Fragment, crystallizable; FcR, Fc receptor; FcRn, neonatal Fc receptor; FDA, Food and Drug Administration; FIH, first-in-human; FOI, Freedom of Information; HED, human equivalent dose; HNSTD, highest nonseverely toxic dose; IB, Investigator’s Brochure; IgG, immunoglobulin isotype G; IL2, Interleukin–2; IMPD, Investigational Medicinal Product Dossier; IND, Investigational New Drug; mAb, monoclonal antibody; MABEL, minimum anticipated biological effect (dose) level; MHRA, Medicines and Healthcare Products Regulatory Agency; MOA, mechanism of ac

Overview

Integrity signals

Registry

Crossref · 10.1177/0192623309332986

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 45 references

Research works printed but not linked: 21

  1. Alegre ML, 1990, Transplant Proc, 22, 1920
  2. Association of the British Pharmaceutical Industry and BioIndustry Association (APBI/BIA), 1977, Guidelines for preclinical testing on new medicinal products. Parts 1 and 2
  3. Association of Food and Drug Officials (AFDO), 1959, Appraisal of the safety of chemicals in food, drugs and cosmetics
  4. BioSafe General Membership Meeting, 2008, Cytokine release assays: Current approaches and considerations
  5. Chatenoud L, 1990, Transplant Proc, 22, 2605
  6. Early Stage Clinical Trial Taskforce, 2007, Early Stage Clinical Trial Taskforce–Joint ABPI/BIA report
  7. European Medicines Agency (EMEA), 2004, Position Paper on Non-Clinical Safety Studies to Support Clinical Trials with a Single Microdose
  8. European Medicines Agency (EMEA), 2007, EMEA guidance for companies requesting scientific advice or protocol assistance
  9. Expert Group on Phase One Clinical Trials (chairman: Professor Gordon W. Duff), 2006, Expert group on phase one clinical trials: Final report
  10. FDA CDER Immunotoxicology Subcommittee Meeting, 2008, Cytokine release: What does it mean to you?
  11. FDA Science Board, Subcommittee on Science and Technology, 2007, FDA science and mission at risk
  12. Gibb F, 2008, The Times
  13. Hale G, 1983, Mol Biol Med, 1, 321
  14. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)ICH harmonised tripartite guideline Statistical principles for clinical trials. E91998(accessed March 28, 2008)http://www.ich.org/LOB/media/MEDIA485.pdf
  15. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)ICH harmonised tripartite guideline. Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. M3(R2). Step 22008aJuly15(accessed August 21, 2008)http://www.ich.org/LOB/media/MEDIA4744.pdf
  16. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)2008b(accessed August 21, 2008)ICH Steering Committee meeting. Monitoring and Protecting the Global Public HealthMay 31–June 5Portland, Oregon, USAhttp://www.ich.org/cache/compo/276-254-1.html
  17. Medicines and Healthcare Products Regulatory Agency (MHRA), 2006, Investigations into adverse incidents during clinical trials of TGN1412 (interim report)
  18. Royal Statistical Society (RSS), 2007, Report of the working party on statistical issues in first-in-man studies
  19. Sims J, 2007, Calculation of the minimum anticipated biological effect level (MABEL) and 1st dose in humans, in EMEA Workshop on the Guideline for First-in-Man Clinical Trials for potential high-risk medicinal products
  20. U.S. Food and Drug Administration (FDA), 2005, Guidance for industry: Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers
  21. U.S. Food and Drug Administration (FDA), 2005, Guidance for industry, investigators, and reviewers: Exploratory IND studies (Draft)

Cited by

See all 87

Metadata

Authors
Horvath, C. J., & Milton, M. N.
Affiliations
  • Taligen Therapeutics, Cambridge, Massachusetts 02142, USA
  • Tempo Pharmaceuticals, Cambridge, Massachusetts 02142, USA
Corresponding author
Horvath, Christopher J.
Venue
Toxicologic Pathology
Published
2009-02-24
Volume
37
Issue
3
Pages
372-383
ISSN
  • 0192-6233 (ISSN-L)
  • 1533-1601
OpenAlex
W2122348862
Cited by
87
References
45
Citations by year
2026: 5 · 2025: 3 · 2024: 5 · 2023: 4 · 2022: 4 · 2021: 3 · 2020: 6 · 2019: 1 · 2018: 11 · 2017: 2 · 2016: 6 · 2015: 4 · 2014: 5 · 2013: 8 · 2012: 4
FWCI
9.63
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Toxicologic Pathology (publishedVersion, public-domain)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Keywords
TGN1412, monoclonal antibodies, regulatory T cells, CD28, T cell activation, adverse drug reactions, drug safety, healthy volunteers, pharmacokinetics, pharmacodynamics
MeSH terms
Antibodies, Monoclonal, Health Planning Guidelines, Humans, Lymphocyte Activation, Pharmacokinetics, Pharmacology, Leukemia, Lymphocytic, Chronic, B-Cell, Clinical Trials, Phase I as Topic, CD28 Antigens, Antibodies, Monoclonal, Humanized, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The TeGenero Incident and the Duff Report Conclusions: A Series of Unfortunate Events or an Avoidable Event? https://app.cochat.ai/papers/10.1177/0192623309332986
The paper
Horvath, C. J., & Milton, M. N. (2009). The TeGenero Incident and the Duff Report Conclusions: A Series of Unfortunate Events or an Avoidable Event? Toxicologic Pathology. https://doi.org/10.1177/0192623309332986

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.